Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Blum, William, Garzon, Ramiro, Klisovic, Rebecca B., Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M., Chan, Kenneth K., Heerema, Nyla A., Bloomfield, Clara D., Grever, Michael R., Byrd, John C., Villalona-Calero, Miguel, Croce, Carlo M., Marcucci, Guido
Médium: Artigo
Jazyk:Inglês
Vydáno: National Academy of Sciences 2010
Témata:
Biological Sciences
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2867720/
https://ncbi.nlm.nih.gov/pubmed/20368434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1002650107
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky